Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed DexCom, Inc. (DXCM)

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false statements and failing to disclose material design changes to its G6 and G7 devices, which may have compromised their reliability and safety [1][2]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized material design changes to the G6 and G7 devices, which were not approved by the U.S. Food and Drug Administration (FDA) [2]. - These design changes reportedly rendered the G6 and G7 devices less reliable than previous versions, posing a significant health risk to users who depend on accurate glucose readings [2]. - The enhancements claimed by DexCom for the G7 device, including its reliability, accuracy, and functionality, were allegedly overstated [2]. - The company is accused of downplaying the severity of issues and health risks associated with the altered G7 devices [2]. - As a result of these actions, DexCom faces increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by DexCom were claimed to be materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who acquired DexCom shares during the class period (July 26, 2024, to September 17, 2025) are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 26, 2025 [3].